Neurocognitive and radiological follow-up of children under 5 years of age treated for medulloblastoma according to the HIT-SKK protocol.
Fiche publication
Date publication
mai 2023
Journal
Journal of neuro-oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CHASTAGNER Pascal, Dr NGUYEN-THI Phi Linh
Tous les auteurs :
Merlin MS, Schmitt E, Mezloy-Destracque M, Dufour C, Riffaud L, Puiseux C, De Carli E, Bodet D, Icher C, Doz F, Faure-Conter C, Pagnier A, Pluchart C, Thouvenin-Doulet S, Lejeune J, Nguyen Thi PL, Chastagner P
Lien Pubmed
Résumé
The HIT-SKK protocol is used for low/standard-risk medulloblastomas in young children with the aim to eliminate cranial irradiation and its neuropsychological (NP) sequelae. This therapy includes IV and intraventricular (ITV) methotrexate (MTX) potentially responsible for leukoencephalopathy (LE) and neurocognitive disorders. This study describes the risk factors and course of LE, and investigates its correlation with neurocognitive impact.
Mots clés
Leukoencephalopathy, Medulloblastoma, Methotrexate, Neurocognitive disorders, Quality of life
Référence
J Neurooncol. 2023 05 12;: